298 filings
Page 6 of 15
6-K
8d7vpu uqxzs
15 May 19
Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
7:56am
6-K
k8tx3dpu
10 May 19
Current report (foreign)
10:05am
6-K
w514p2s66r1v1bqcmt4u
24 Apr 19
Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
8:35am
6-K
roh26d
15 Apr 19
Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
9:15am
6-K
8fukpf4vpile fkf
26 Mar 19
Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
8:30am
6-K
a85cgsm
13 Mar 19
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
8:30am
6-K
z01 vbzhbncwakttgsaw
21 Feb 19
Current report (foreign)
9:15am
6-K
qkz8tlvbcrc7 31x2zlo
14 Feb 19
At Market Issuance Sales Agreement
8:13am
6-K
6yhxk fudr9cqhi
14 Feb 19
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
8:05am
6-K
0beyad3
14 Feb 19
Current report (foreign)
7:55am
6-K
o1mkczlriok
8 Feb 19
Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
8:05am
6-K
tmfik 83id0x
9 Jan 19
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
8:05am
6-K
dtecx4
31 Dec 18
Current report (foreign)
8:00am
6-K
aqr9y4cha4
20 Dec 18
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
8:01am
6-K
nkeuj983pmw 8aa302l
14 Nov 18
Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
8:05am
6-K
jvccuwd
14 Nov 18
Current report (foreign)
7:00am
6-K
mc9u9 r13u
7 Nov 18
Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
8:01am
6-K
b5apukxq0vcd6
23 Oct 18
Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
9:21am
6-K
lgf53p
15 Oct 18
Current report (foreign)
5:15pm
6-K
ukbnor1 o5hax09p87
11 Oct 18
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
7:42am